Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00390000 · ClinicalTrials.gov registry record · Phase 1
Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT00390000: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT00390000 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 29 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00390000, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
RATIONALE: Vatalanib and pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vatalanib may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving vatalanib together with pemetrexed disodium may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vatalanib when given together with pemetrexed disodium in treating patients with advanced solid tumors.
Interventions
- OTHER pharmacological study
- PROCEDURE ultrasound imaging
- DRUG pemetrexed disodium
- DRUG vatalanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2007-01-25 |
| Est. Completion | 2016-08-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00390000
The ClinicalTrials.gov registry entry for NCT00390000 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which pharmacological study is the first listed.
NCT00390000 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00390000 about?
NCT00390000 is a clinical study titled "Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors". RATIONALE: Vatalanib and pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vatalanib may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving vatalanib together with pemetrexed disodium may kill more tumor cells....
What is the current status of trial NCT00390000?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2007-01-25. Estimated completion is 2016-08-04.
What interventions are being tested in trial NCT00390000?
The interventions under investigation include: pharmacological study (OTHER), ultrasound imaging (PROCEDURE), pemetrexed disodium (DRUG), vatalanib (DRUG).
Who is sponsoring clinical trial NCT00390000?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.